US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Corgi U.S. Healthcare 2x Daily ETF

32.03

0.0000

Volume:19

Turnover:605.06

Market Cap:640.64K

PE:- -

High:32.03

Open:32.03

Low:32.03

Close:32.03

52wk High:35.56

52wk Low:25.40

Shares:20.00K

Float Shares:20.00K

Volume Ratio:0.03

T/O Rate:0.10%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Barclays downgrades Scholar Rock on valuation after FDA approval

Biofrontera announces FDA approval of Ameluz supplemental new drug application

Scholar Rock Wins FDA Approval for SMA Therapy

Scholar Rock price target raised to $84 from $76 at BMO Capital

Telix Wins FDA Nod for First FET-PET Glioma Imaging Drug Pixclara

Scholar Rock announces FDA approval of isembyld

Pharming wins FDA nod to extend Joenja use to younger APDS children

Medicare Advantage Patients Who Get Diagnosed with Alzheimer's or Other Serious Diseases are Ditching Their Plans - and it Can Cost Them

Guardant announces FDA approval of Guardant360 CDx as companion diagnostic

Medicare Advantage Patients Who Get Diagnosed with Alzheimer's or Other Serious Diseases are Ditching Their Plans - and it Can Cost Them

Medicare Advantage Patients Who Get Diagnosed with Alzheimer's or Other Serious Diseases are Ditching Their Plans - and it Can Cost Them

Protagonist announces Takeda received U.S. FDA approval for MIMRYLO

Takeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO

Takeda receives FDA approval of NDA for Mimrylo

Roche receives FDA approval for companion diagnostic tests for Ziihera

Revolution Medicines prices Rasonque at $39,800 for 30-day supply

Revolution Medicines announces FDA approval of Rasonque in adults

Humana (HUM) Targets 10,000 Medicare Advantage Members In Kidney Care Partnership

Simply Wall St.

BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA

Think Medicare Advantage Provides Better Care for Chronic Conditions? a New Study Suggests Otherwise.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/XLVX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"XLVX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XLVX\",,,,,undefined,":{"symbol":"XLVX","market":"US","secType":"STK","nameCN":"Corgi U.S. Healthcare 2x Daily ETF","latestPrice":32.032,"timestamp":1789489482798,"preClose":32.032,"halted":0,"volume":19,"delay":0,"changeRate":0,"floatShares":20000,"shares":20000,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"09-15 12:42:29 EDT","open":32.032,"high":32.032,"low":32.032,"amount":605.057128,"amplitude":0,"askPrice":32.09,"askSize":200,"bidPrice":32,"bidSize":200,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789502400000},"marketStatusCode":2,"adr":0,"exchange":"CBOE","adjPreClose":32.032,"nav":31.11,"aum":622200,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":31.1534,"preClose":32.032,"latestTime":"19:50 EDT","volume":5,"amount":160.158,"timestamp":1789429820232,"change":-0.8786,"changeRate":-0.027429,"amplitude":0},"volumeRatio":0.029421},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XLVX\",,,,,undefined,":{"symbol":"XLVX","floatShares":20000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.029421,"shares":20000,"dividePrice":0,"high":32.032,"amplitude":0,"preClose":32.032,"low":32.032,"week52Low":25.3968,"pbRate":"--","week52High":35.56,"institutionHeld":0,"latestPrice":32.032,"eps":0,"divideRate":0,"volume":19,"delay":0,"ttmEps":0,"open":32.032,"prevYearClose":25.46,"prevWeekClose":31.1534,"prevMonthClose":33.2893,"prevQuarterClose":29.402,"fiveDayClose":31.847,"twentyDayClose":32.0285,"sixtyDayClose":27.1193},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XLVX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XLVX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XLVX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XLVX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667643557","title":"Barclays downgrades Scholar Rock on valuation after FDA approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2667643557","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667643557?lang=en_us&edition=fundamental","pubTime":"2026-09-15 17:10","pubTimestamp":1789463419,"startTime":"0","endTime":"0","summary":"Barclays analyst Etzer Darout downgraded Scholar Rock (SRRK) to Equal Weight from Overweight with a price target of $58, up from $55. The approval ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/barclays-downgrades-scholar-rock-on-valuation-after-fda-approval-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/barclays-downgrades-scholar-rock-on-valuation-after-fda-approval-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CDIG","IBB","TACU","LFSC","FRTY","PINK","SYNB","TBXU","TSPA","TECB","LABU","PSCH","GNMX","MEDI","BBP","RSPH","MRNY","BMED","IYH","XLVX","IDNA","GDOC","NVIB","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667661630","title":"Biofrontera announces FDA approval of Ameluz supplemental new drug application","url":"https://stock-news.laohu8.com/highlight/detail?id=2667661630","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667661630?lang=en_us&edition=fundamental","pubTime":"2026-09-14 21:35","pubTimestamp":1789392922,"startTime":"0","endTime":"0","summary":"Biofrontera (BFRI) announced that the FDA has approved the company’s supplemental new drug application, or sNDA, for Ameluz topical gel, 10%, in co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biofrontera-announces-fda-approval-of-ameluz-supplemental-new-drug-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biofrontera-announces-fda-approval-of-ameluz-supplemental-new-drug-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNX","IEIH","IYH","SYNB","TBXU","IDNA","FRTY","MEDI","PINK","GNMX","LABU","PSCH","RSPH","BK4007","LFSC","BK4588","IBB","BK4585","TECB","XLVX","MRNY","BFRI","GDOC","BMED","NVIB","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667066661","title":"Scholar Rock Wins FDA Approval for SMA Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2667066661","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667066661?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:32","pubTimestamp":1789389127,"startTime":"0","endTime":"0","summary":"The latest update is out from Scholar Rock Holding ( ($SRRK) ). On September 11, 2026, Scholar Rock announced U.S. FDA approval of ISEMBYLD (apiteg...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/scholar-rock-wins-fda-approval-for-sma-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/scholar-rock-wins-fda-approval-for-sma-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","IYH","MRNY","TECB","PSCH","IDNA","MEDI","PINK","BMED","SYNB","FRTY","XLVX","LABU","NVIB","BK4585","BBP","GNMX","IEIH","MRNX","LFSC","GDOC","TBXU","RSPH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667134663","title":"Scholar Rock price target raised to $84 from $76 at BMO Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2667134663","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667134663?lang=en_us&edition=fundamental","pubTime":"2026-09-14 19:36","pubTimestamp":1789385772,"startTime":"0","endTime":"0","summary":"BMO Capital raised the firm’s price target on Scholar Rock (SRRK) to $84 from $76 and keeps an Outperform rating on the shares. The FDA approval of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-price-target-raised-to-84-from-76-at-bmo-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-price-target-raised-to-84-from-76-at-bmo-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDI","SYNB","BK4139","MRNY","SRRK","IEIH","FRTY","BK4588","BK4585","MRNX","IBRN","LFSC","IBB","GDOC","BBP","BMED","PSCH","GNMX","TECB","XLVX","THNR","NVIB","RSPH","IDNA","IYH","LABU","PINK","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667635862","title":"Telix Wins FDA Nod for First FET-PET Glioma Imaging Drug Pixclara","url":"https://stock-news.laohu8.com/highlight/detail?id=2667635862","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667635862?lang=en_us&edition=fundamental","pubTime":"2026-09-14 06:54","pubTimestamp":1789340092,"startTime":"0","endTime":"0","summary":"The latest update is out from Telix Pharmaceuticals ( ($AU:TLX) ). Telix Pharmaceuticals has secured U.S. FDA approval for Pixclara, the first FET-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-wins-fda-nod-for-first-fet-pet-glioma-imaging-drug-pixclara?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-wins-fda-nod-for-first-fet-pet-glioma-imaging-drug-pixclara?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","XLVX","MRNY","PSCH","IYH","BMED","FRTY","BK4588","IDNA","IEIH","SYNB","GDOC","RSPH","TECB","LFSC","GNMX","BK4585","BK4139","NVIB","LABU","PINK","TLX","MEDI","FET","TBXU","BBP","MRNX","BK4179"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666577803","title":"Scholar Rock announces FDA approval of isembyld","url":"https://stock-news.laohu8.com/highlight/detail?id=2666577803","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666577803?lang=en_us&edition=fundamental","pubTime":"2026-09-12 06:30","pubTimestamp":1789165818,"startTime":"0","endTime":"0","summary":"Scholar Rock (SRRK) announced that the FDA has approved isembyld for the treatment of spinal muscular atrophy in adults and children two years of a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-announces-fda-approval-of-isembyld-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-announces-fda-approval-of-isembyld-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBP","THNR","RSPH","IBB","MRNX","PSCH","IBRN","NVIB","SRRK","IYH","BK4588","SYNB","PINK","LABU","BMED","TECB","BK4585","FRTY","LFSC","MRNY","TBXU","XLVX","MEDI","GDOC","GNMX","IEIH","IDNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666795715","title":"Pharming wins FDA nod to extend Joenja use to younger APDS children","url":"https://stock-news.laohu8.com/highlight/detail?id=2666795715","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666795715?lang=en_us&edition=fundamental","pubTime":"2026-09-12 02:32","pubTimestamp":1789151567,"startTime":"0","endTime":"0","summary":"Pharming Group ( ($NL:PHARM) ) has provided an announcement. Pharming has secured U.S. FDA approval for new 40 mg and 50 mg twice-daily doses of Jo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pharming-wins-fda-nod-to-extend-joenja-use-to-younger-apds-children?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pharming-wins-fda-nod-to-extend-joenja-use-to-younger-apds-children?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLVX","BBP","IYH","TBXU","GNMX","IEIH","LFSC","IBB","SYNB","LABU","MRNX","NVIB","MRNY","BK4585","PINK","PSCH","FRTY","BMED","TECB","BK4588","RSPH","GDOC","IDNA","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665458363","title":"Medicare Advantage Patients Who Get Diagnosed with Alzheimer's or Other Serious Diseases are Ditching Their Plans - and it Can Cost Them","url":"https://stock-news.laohu8.com/highlight/detail?id=2665458363","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665458363?lang=en_us&edition=fundamental","pubTime":"2026-09-05 22:15","pubTimestamp":1788617700,"startTime":"0","endTime":"0","summary":"The annual Medicare open-enrollment period runs from Oct. 15 to Dec. 7Medicare Advantage plans cover more than half of the total Medicare market of 70.5 million subscribers, according to the Centers f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","BK4588","LU1093756325.SGD","SG9999014021.USD","LU0211331839.USD","LU0417517546.SGD","BK4154","IYH","UN","LU0320765489.SGD","LNGR","LU1983260115.SGD","HUM","UNHU","UNHW","SG9999014013.SGD","LU0070302665.USD","LU0266013472.USD","IEHS","LU0348723411.USD","LU0208291251.USD","LU0238689110.USD","LU1093756168.USD","XLVX","LU0170899867.USD","BK4566","FXH","LU0390134368.USD","SG9999014005.SGD","UNHG","IHF","LU0256863811.USD","BK4585","XHS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665354019","title":"Guardant announces FDA approval of Guardant360 CDx as companion diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=2665354019","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665354019?lang=en_us&edition=fundamental","pubTime":"2026-09-05 06:15","pubTimestamp":1788560112,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced that the U.S. Food and Drug Administration has approved Guardant360 CDx as a companion diagnostic to identify patien...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-announces-fda-approval-of-guardant360-cdx-as-companion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-announces-fda-approval-of-guardant360-cdx-as-companion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","PTH","GNMX","MEDI","FFOX","EKG","BK4535","GNOM","XLVX","BBP","IDNA","GDOC","TECB","NVIB","PINK","HELX","MRNX","LU0889565916.HKD","TBXU","LU0320765992.SGD","BK4196","LABU","GH","LU0109394709.USD","BK4551","FRTY","IEIH","IBB","SYNB","IYH","BK4588","RSPH","BMED","MRNY","LFSC","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664805403","title":"Medicare Advantage Patients Who Get Diagnosed with Alzheimer's or Other Serious Diseases are Ditching Their Plans - and it Can Cost Them","url":"https://stock-news.laohu8.com/highlight/detail?id=2664805403","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664805403?lang=en_us&edition=fundamental","pubTime":"2026-09-04 01:23","pubTimestamp":1788456180,"startTime":"0","endTime":"0","summary":"The annual Medicare open-enrollment period runs from Oct. 15 to Dec. 7Medicare Advantage plans cover more than half of the total Medicare market of 70.5 million subscribers, according to the Centers f","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0266013472.USD","LU1093756168.USD","LU0170899867.USD","IEHS","IHF","LU0211331839.USD","UNHW","LU0238689110.USD","LNGR","LU0256863811.USD","XHS","IYH","LU0417517546.SGD","LU0070302665.USD","UNHG","LU0390134368.USD","UNHU","SG9999014005.SGD","BK4533","BK4585","XLVX","LU1093756325.SGD","LU0348723411.USD","LU0320765489.SGD","BK4154","LU1983260115.SGD","UN","BK4566","HUM","LU0208291251.USD","FXH","SG9999014013.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664443848","title":"Medicare Advantage Patients Who Get Diagnosed with Alzheimer's or Other Serious Diseases are Ditching Their Plans - and it Can Cost Them","url":"https://stock-news.laohu8.com/highlight/detail?id=2664443848","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664443848?lang=en_us&edition=fundamental","pubTime":"2026-09-03 00:04","pubTimestamp":1788365040,"startTime":"0","endTime":"0","summary":"The annual Medicare open-enrollment period runs from Oct. 15 to Dec. 7Medicare Advantage plans cover more than half of the total Medicare market of 70.5 million subscribers, according to the Centers f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HUM","LU0070302665.USD","LU0390134368.USD","LU0211331839.USD","XHS","FXH","BK4588","XLVX","LU0348723411.USD","LU1093756325.SGD","LU1093756168.USD","BK4533","LU1983260115.SGD","LNGR","BK4566","LU0417517546.SGD","LU0208291251.USD","UNHU","IEHS","UN","SG9999014005.SGD","LU0238689110.USD","BK4154","IYH","LU0266013472.USD","BK4585","UNHW","LU0170899867.USD","IHF","LU0256863811.USD","SG9999014013.SGD","UNHG","LU0320765489.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663588047","title":"Protagonist announces Takeda received U.S. FDA approval for MIMRYLO","url":"https://stock-news.laohu8.com/highlight/detail?id=2663588047","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663588047?lang=en_us&edition=fundamental","pubTime":"2026-08-31 04:35","pubTimestamp":1788122107,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics (PTGX) announced that Takeda (TAK) received U.S. Food and Drug Administration, FDA, approval for MIMRYLO, a subcutaneously...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/protagonist-announces-takeda-received-u-s-fda-approval-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/protagonist-announces-takeda-received-u-s-fda-approval-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","PINK","LFSC","BK4139","NVIB","TECB","IEIH","BMED","BBP","BK4585","PSCH","RSPH","SYNB","TBXU","BK4588","IBB","MRNX","GNMX","IDNA","IYH","XLVX","BK4007","MEDI","PTGX","FRTY","TAK","GDOC","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663019703","title":"Takeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO","url":"https://stock-news.laohu8.com/highlight/detail?id=2663019703","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663019703?lang=en_us&edition=fundamental","pubTime":"2026-08-29 08:52","pubTimestamp":1787964735,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical Co ( ($JP:4502) ) just unveiled an announcement. Takeda has secured U.S. FDA approval for MIMRYLO (rusfertide), a first-in-cl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takeda-wins-fda-nod-for-first-in-class-polycythemia-vera-therapy-mimrylo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takeda-wins-fda-nod-for-first-in-class-polycythemia-vera-therapy-mimrylo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TBXU","NVIB","PSCH","MRNX","BBP","TECB","BMED","BK4588","GNMX","LABU","IBB","SYNB","MRNY","RSPH","XLVX","IDNA","BK4585","FRTY","PINK","GDOC","MEDI","IYH","IEIH","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663016033","title":"Takeda receives FDA approval of NDA for Mimrylo","url":"https://stock-news.laohu8.com/highlight/detail?id=2663016033","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663016033?lang=en_us&edition=fundamental","pubTime":"2026-08-29 07:00","pubTimestamp":1787958013,"startTime":"0","endTime":"0","summary":"Takeda (TAK) announced U.S. FDA approval of the New Drug Application for Mimrylo for the treatment of erythrocytosis in adults with polycythemia ve...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/takeda-receives-fda-approval-of-nda-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/takeda-receives-fda-approval-of-nda-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLVX","NVIB","SYNB","BMED","GDOC","LFSC","TECB","IYH","PINK","GNMX","FRTY","IBB","RSPH","BBP","PSCH","MRNY","TBXU","MRNX","TAK","BK4007","BK4585","MEDI","IDNA","LABU","IEIH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662874134","title":"Roche receives FDA approval for companion diagnostic tests for Ziihera","url":"https://stock-news.laohu8.com/highlight/detail?id=2662874134","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662874134?lang=en_us&edition=fundamental","pubTime":"2026-08-27 03:00","pubTimestamp":1787770816,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) announced that it has received FDA approval for expanded use of its PATHWAY HER2 and VENTANA HER2 Dual ISH DNA Probe Cocktail tests. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-receives-fda-approval-for-companion-diagnostic-tests-for-ziihera-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-receives-fda-approval-for-companion-diagnostic-tests-for-ziihera-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNMX","BK4007","GDOC","PINK","RHHBY","BK4585","FRTY","LFSC","NVIB","MEDI","XLVX","IYH","CANC","BMED","IBB","TECB","LABU","IEIH","PSCH","HRTS","MRNY","RSPH","IDNA","SYNB","TBXU","BK4588","MRNX","BBP","03165"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662797746","title":"Revolution Medicines prices Rasonque at $39,800 for 30-day supply","url":"https://stock-news.laohu8.com/highlight/detail?id=2662797746","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662797746?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:45","pubTimestamp":1787766320,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) disclosed that following FDA approval of Rasonque for the treatment of adult patients with metastatic pancreatic adenoc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-prices-rasonque-at-39800-for-30-day-supply-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-prices-rasonque-at-39800-for-30-day-supply-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RSPH","LU0889565916.HKD","GDOC","MRNY","SYNB","PTH","IE00BFTCPJ56.SGD","LABU","LU0320765992.SGD","NVIB","PINK","BMED","TECB","BBH","XLVX","IEIH","TBXU","CANC","IE0002141913.USD","IYH","MEDI","IE00B4R5TH58.HKD","BBP","IBB","PSCH","LFSC","LU0109394709.USD","BK4139","IE0009355771.USD","BK4585","BK4588","FRTY","RVMD","IE00B2B36J28.USD","IDNA","IE00BJJMRZ35.SGD","GNMX","MRNX","IE00BJT1NW94.SGD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662074659","title":"Revolution Medicines announces FDA approval of Rasonque in adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2662074659","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662074659?lang=en_us&edition=fundamental","pubTime":"2026-08-27 01:05","pubTimestamp":1787763925,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) announced that the U.S. Food and Drug Administration has approved RASONQUE once-daily oral tablets, for the treatment o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-announces-fda-approval-of-rasonque-in-adults-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-announces-fda-approval-of-rasonque-in-adults-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNMX","FRTY","PINK","RSPH","IYH","MRNY","TBXU","BBH","BK4588","PSCH","BK4585","IDNA","TECB","IEIH","SYNB","LFSC","BK4139","IE00BJT1NW94.SGD","PTH","IE0009354923.USD","LU0320765992.SGD","BBP","MEDI","LABU","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE0009355771.USD","GDOC","XLVX","MRNX","IE0002141913.USD","LU0109394709.USD","NVIB","IE00B4R5TH58.HKD","RVMD","IE00B2B36J28.USD","BMED","CANC","IE00BFTCPJ56.SGD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662915759","title":"Humana (HUM) Targets 10,000 Medicare Advantage Members In Kidney Care Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2662915759","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662915759?lang=en_us&edition=fundamental","pubTime":"2026-08-26 01:18","pubTimestamp":1787678306,"startTime":"0","endTime":"0","summary":"Humana (NYSE:HUM) and DaVita have launched a new coordinated value-based care partnership for Medicare Advantage members with chronic kidney disease.\nThe program targets over 10,000 Medicare Advantage members and focuses on earlier intervention to slow disease progression and reduce hospitalizations.\nThe collaboration expands Humana's value-based care model by integrating DaVita's kidney care expertise into Humana's existing Medicare Advantage footprint.\n\nFor investors tracking how health...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/29618-main-header/1756204961955","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/29618-main-header/1756204961955"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/humana-hum-targets-10000-medicare-advantage-members-in-kidne","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/humana-hum-targets-10000-medicare-advantage-members-in-kidne","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1093756168.USD","BK4588","BK4533","IHF","LU0238689110.USD","LU1983260115.SGD","LU0320765489.SGD","FXH","LU0208291251.USD","LU0266013472.USD","UNHU","LU0170899867.USD","BK4154","UN","SG9999014013.SGD","LU0417517546.SGD","LU0070302665.USD","LU0211331839.USD","SG9999014021.USD","IEHS","LU1093756325.SGD","SG9999014005.SGD","LNGR","UNHG","LU0390134368.USD","BK4585","LU0348723411.USD","HUM.AU","IYH","LU0256863811.USD","BK4566","BK7093","HUM","UNHW","XLVX","XHS","BK7500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662530687","title":"BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA","url":"https://stock-news.laohu8.com/highlight/detail?id=2662530687","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662530687?lang=en_us&edition=fundamental","pubTime":"2026-08-25 22:45","pubTimestamp":1787669120,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) announced that the U.S. FDA has approved the supplemental Biologics License Application for TEVIMBRA in combination with ZIIH...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-announces-fda-approval-for-tevimbra-based-reginmen-for-her2-gea-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-announces-fda-approval-for-tevimbra-based-reginmen-for-her2-gea-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","MRNY","LFSC","LABU","PSCH","NVIB","IEIH","MRNX","XLVX","BBP","BK4585","GNMX","PINK","BK4526","GDOC","SYNB","IBB","RSPH","IDNA","TBXU","TECB","IYH","BK4588","MEDI","BK4139","ONC","FRTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661274273","title":"Think Medicare Advantage Provides Better Care for Chronic Conditions? a New Study Suggests Otherwise.","url":"https://stock-news.laohu8.com/highlight/detail?id=2661274273","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661274273?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:19","pubTimestamp":1787570340,"startTime":"0","endTime":"0","summary":"Medicare Advantage enrollees with diabetes aren't healthier than Americans on traditional Medicare - despite the grocery and gym perksA new study examined whether people who enroll in Medicare Advanta","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","LU0390134368.USD","LU0170899867.USD","UNHW","LU0208291251.USD","BK4566","SG9999014013.SGD","IHF","IEHS","LU0266013472.USD","BK4588","XLVX","SG9999014021.USD","LU0070302665.USD","SG9999014005.SGD","LU0211331839.USD","BK4585","LU0238689110.USD","UN","IYH","UNHU","LNGR","LU0417517546.SGD","LU0256863811.USD","LU1093756325.SGD","LU1983260115.SGD","UNHG","XHS","LU0348723411.USD","FXH","LU1093756168.USD","BK4154","LU0320765489.SGD","HUM"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":52,"code":"91000000","status":"200"}]}}